Poseida Therapeutics

Poseida Therapeutics

Poseida Therapeutics develops targeted cell therapy.

All edits

Edits on 13 June, 2020
Henry Ogolla
Henry Ogolla edited on 13 June, 2020 7:43 pm
Edits made to:
Timeline (+1 events) (+164 characters)
Timeline

May 20, 2020

Poseida Therapeutics announces dosing of first patient in phase 1 clinical trial of P-PSMA-101 autologous CAR-T for metastatic castration-resistant prostate cancer.

Edits on 11 June, 2020
Golden AI"IBI-141"
Golden AI edited on 11 June, 2020 7:48 pm
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 18 April, 2020
Golden AI
Golden AI edited on 18 April, 2020 5:44 am
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 3 March, 2020
Golden AI
Golden AI edited on 3 March, 2020 5:20 am
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 3 September, 2019
Golden AI
Golden AI edited on 3 September, 2019 6:46 pm
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 15 February, 2019
Carla Faraguna
Carla Faraguna edited on 15 February, 2019 6:23 pm
Edits made to:
Infobox (+3 properties)
Infobox
Sameeha Sulaiman
Sameeha Sulaiman edited on 15 February, 2019 2:39 pm
Edits made to:
Article (+996/-6 characters)
Further reading (+1 rows) (+3 cells) (+184 characters)
Article

Poseida's leading product candidate is P-BCMA-101, an autologous CAR-T product that targets B cell maturation antigen, or BCMA, which is expressed on multiple myeloma cells. In December 2018, the compaycompany announced positive results from its first cohort of ongoing Phase 1 clinical trial. Poseida's second autologous product is P-PSMA-101, targeting cells that express prostate-specific membrane antigen, which is expressed on most prostate cancer cells. The product is being developed to treat patients with castrate-resistance prostate cancer, or CRPC, a solid tumor indication, with Phase 1 clinical trials planned in the second half of 2019.

Under the allogenic category, Poseida has P-BCMA-ALL01 and P-MUC1C-101. Derived from healthy donors, P-BCMA-ALL01 is designed to have the same inherent properties and functions of P-BCMA-101, but with the benefits of scale and administration efficiency that come from an allogenic product. The company plans to file an IND and begin Phase 1 clinical trials by late 2019 or early 2020. As for P-MUC1C-101, the product is in late-stage pre-clinical development for multiple solid tumor indications with plans for Phase 1 clinical trials in 2020.

In January 2019, Poseida Therapeutics filed documents for an IPO of $115 million.

Further reading

Title
Author
Link
Type

Xconomy: Poseida Therapeutics Prepares for IPO to Advance CAR-T Treatments

Web

Sameeha Sulaiman
Sameeha Sulaiman edited on 15 February, 2019 2:23 pm
Edits made to:
Infobox (+3/-1 properties)
Article (+704/-227 characters)
People (+11 rows) (+22 cells) (+467 characters)
Further reading (+1 rows) (+4 cells) (+396 characters)
Article

Poseida's CAR T cell therapy is genetically engineered immune cells that hone in on a cellular target present on the cancer cells, but not on any essential cells.

Poseida Therapeutics is a privately held, biopharmaceutical company based in San Diego California. It leverages proprietary non-viral, gene engineering technologies to create therapeutics for illnesses with high unmet medical needs. The company is developing a wholly-owned pipeline of autologous and allogenic CAR-T product candidates, initially focused on the treatment of hematological malignancies and other solid tumors.

...

On April 3, 2018, Poseida announced $30.5m in series B funding.

Poseida's leading product candidate is P-BCMA-101, an autologous CAR-T product that targets B cell maturation antigen, or BCMA, which is expressed on multiple myeloma cells. In December 2018, the compay announced positive from its first cohort of ongoing Phase 1 clinical trial.

People

Name
Role
Related Golden topics

Debra Gessner

VP, Regulatory Affairs

Devon J. Shedlock

VP, Preclinical Development

Glenn Dourado

VP, Business Development

Jeff Knight

VP, Clinical Development Operations and Project Management

Jennifer Collins

VP, Quality Operations

Johanna Mylet

VP, Finance

Marcy Graham

VP, Corporate Affairs

Mark J. Gergen

Chief Business Officer and Chief Financial Officer

Martin Giedlin

VP, Technical Operations

Matthew A. Spear

Chief Medical Officer

Paiman Peter Ghoroghchian

Chief Technical Officer

Further reading

Title
Author
Link
Type

Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting

Poseida Therapeutics, Inc.

Web

Infobox
Edits on 6 December, 2018
Carla Faraguna
Carla Faraguna edited on 6 December, 2018 6:57 pm
Edits made to:
Categories (+1 topics)
Categories
Edits on 23 August, 2018
Carla Faraguna"Added information about the company and details to the infobox."
Carla Faraguna edited on 23 August, 2018 12:29 am
Edits made to:
Infobox (+2 properties)
Description (+52 characters)
Article (+227 characters)
People (+1 rows) (+2 cells) (+16 characters)
Topic thumbnail

Poseida Therapeutics

Poseida Therapeutics develops targeted cell therapy.

Article

Poseida's CAR T cell therapy is genetically engineered immune cells that hone in on a cellular target present on the cancer cells, but not on any essential cells.

...

On April 3, 2018, Poseida announced $30.5m in series B funding.

People

Name
Role
Related Golden topics

Eric Ostertag

CEO

Infobox
Edits on 21 April, 2018
Melanie Manipula
Melanie Manipula edited on 21 April, 2018 12:08 am
Edits made to:
Topic thumbnail

Poseida Therapeutics

Poseida Therapeutics develops targeted cell therapy.

Melanie Manipula"Initial topic creation"
Melanie Manipula created this topic on 20 April, 2018 11:57 pm
Edits made to:
Description
Academic papers
People
Further reading
Documentaries, videos and podcasts
Companies
Products
Topic thumbnail

 Poseida Therapeutics

Poseida Therapeutics develops targeted cell therapy.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.